

# David I Rosenthal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1016971/publications.pdf>

Version: 2024-02-01

346  
papers

25,403  
citations

7551

77  
h-index

8599

146  
g-index

353  
all docs

353  
docs citations

353  
times ranked

19345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 24-35.	13.9	5,481
2	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. <i>Journal of Clinical Oncology</i> , 2014, 32, 2940-2950.	0.8	697
3	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 960-970.	0.4	643
4	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	0.8	449
5	CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCR, NRG Oncology and TROG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2015, 117, 83-90.	0.3	425
6	Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity. <i>Journal of Clinical Oncology</i> , 2014, 32, 3858-3867.	0.8	363
7	Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2636-2643.	0.8	358
8	Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1345.	2.2	261
9	Parathyroid carcinoma: A 22-year experience. <i>Head and Neck</i> , 2004, 26, 716-726.	0.9	233
10	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. <i>Head and Neck</i> , 2007, 29, 923-931.	0.9	227
11	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1221-1237.	5.1	226
12	Prophylactic Gastrostomy Tubes in Patients Undergoing Intensive Irradiation for Cancer of the Head and Neck. <i>JAMA Otolaryngology</i> , 1998, 124, 871.	1.5	218
13	IMRT Reirradiation of Head and Neck Cancer—Disease Control and Morbidity Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 399-409.	0.4	218
14	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 156-164.	0.8	216
15	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
16	Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3964-3971.	0.8	210
17	The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2009, 115, 5723-5733.	2.0	210
18	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5119-5125.	0.8	206

#	ARTICLE	IF	CITATIONS
19	Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1300-1308.	0.8	190
20	Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. <i>Head and Neck</i> , 2002, 24, 115-126.	0.9	189
21	Sinonasal malignancies with neuroendocrine differentiation. <i>Cancer</i> , 2004, 101, 2567-2573.	2.0	187
22	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 782.	3.4	185
23	Epithelial to mesenchymal transition in head and neck squamous carcinoma. <i>Cancer</i> , 2008, 112, 2088-2100.	2.0	184
24	Differential Expression of Hormonal and Growth Factor Receptors in Salivary Duct Carcinomas. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1645-1652.	2.1	179
25	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.3	177
26	Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. <i>Annals of Thoracic Surgery</i> , 2003, 76, 1635-1642.	0.7	169
27	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 747-755.	0.4	168
28	Adaptive radiotherapy for head and neck cancer – Dosimetric results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2013, 106, 80-84.	0.3	168
29	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1559-1569.	0.4	165
30	A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 1435-1446.	3.2	164
31	Prospective Risk-Adjusted [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2509-2515.	0.8	156
32	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1356-1365.	0.4	156
33	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF</i> <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1036-1043.	2.4	156
34	Photodynamic Therapy in the Treatment of Cancer. <i>Drugs</i> , 1999, 57, 725-734.	4.9	153
35	Strategies for Managing Radiation-Induced Mucositis in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2009, 19, 29-34.	1.0	153
36	Sinonasal adenoid cystic carcinoma. <i>Cancer</i> , 2007, 110, 2726-2731.	2.0	148

#	ARTICLE	IF	CITATIONS
37	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1083-1091.	0.4	143
38	Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 3825-3830.	3.2	140
39	Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. <i>Journal of Clinical Oncology</i> , 2007, 25, 3971-3977.	0.8	136
40	How should we measure and report radiotherapy-induced xerostomia?. <i>Seminars in Radiation Oncology</i> , 2003, 13, 226-234.	1.0	135
41	Conditional survival in head and neck squamous cell carcinoma. <i>Cancer</i> , 2007, 109, 1331-1343.	2.0	134
42	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 438-444.	0.4	130
43	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1290-1296.	0.4	130
44	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 846-853.	0.4	128
45	Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 4057-4065.	0.8	124
46	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 30-41.	0.4	123
47	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.4	121
48	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 674-681.	0.4	119
49	Induction Chemotherapy for Advanced Squamous Cell Carcinoma of the Paranasal Sinuses. <i>JAMA Otolaryngology</i> , 2011, 137, 78.	1.5	113
50	Comparison of 2D Radiographic Images and 3D Cone Beam Computed Tomography for Positioning Head-and-Neck Radiotherapy Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 916-925.	0.4	112
51	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	2.0	109
52	Sarcomatoid Carcinoma of the Head and Neck. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1216-1220.	2.1	106
53	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. <i>Cancer</i> , 2014, 120, 1975-1984.	2.0	106
54	Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18f-fluoro-2-deoxy-D-glucose positron emission tomography. <i>Laryngoscope</i> , 1999, 109, 970-975.	1.1	105

#	ARTICLE	IF	CITATIONS
55	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 66-74.	0.8	103
56	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. <i>Head and Neck</i> , 2016, 38, E1886-95.	0.9	102
57	Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A decade survey. <i>Cancer</i> , 2015, 121, 1608-1619.	2.0	100
58	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1117-1131.	0.4	100
59	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 941-947.	0.4	99
60	Relative Risk of Stroke in Head and Neck Carcinoma Patients Treated With External Cervical Irradiation. <i>Laryngoscope</i> , 2002, 112, 1883-1887.	1.1	96
61	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 321-325.	0.3	96
62	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.4	96
63	Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2489-2496.	0.8	94
64	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 204-209.	0.4	94
65	Lymphedema Outcomes in Patients with Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 284-291.	1.1	91
66	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1–2 Glottic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 455-461.	0.4	89
67	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. <i>Radiation Oncology</i> , 2013, 8, 21.	1.2	89
68	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. <i>Medical Dosimetry</i> , 2013, 38, 390-394.	0.4	88
69	Optimization of long-term outcomes for patients with esthesioneuroblastoma. <i>Head and Neck</i> , 2014, 36, 524-530.	0.9	88
70	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.4	88
71	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 719-730.	0.4	86
72	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1002-1011.	0.4	86

#	ARTICLE	IF	CITATIONS
73	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 304-314.	0.3	85
74	Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. <i>Cancer</i> , 2012, 118, 3337-3344.	2.0	84
75	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 678-683.	0.4	83
76	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. <i>Head and Neck</i> , 2010, 32, 829-836.	0.9	80
77	Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era. <i>Head and Neck</i> , 2008, 30, 883-888.	0.9	78
78	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. <i>Radiotherapy and Oncology</i> , 2016, 121, 381-386.	0.3	78
79	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. <i>Cancer</i> , 2003, 98, 2322-2328.	2.0	77
80	Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. <i>Oral Oncology</i> , 2013, 49, 360-366.	0.8	76
81	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. <i>International Journal of Particle Therapy</i> , 2015, 2, 19-28.	0.9	76
82	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1005-1010.	0.4	75
83	Swallowing Outcomes After Radiotherapy for Laryngeal Carcinoma. <i>JAMA Otolaryngology</i> , 2008, 134, 178.	1.5	74
84	The M. D. Anderson Symptom Inventory—Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1355-1361.	0.4	72
85	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. <i>Head and Neck</i> , 2006, 28, 967-973.	0.9	70
86	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. <i>Radiotherapy and Oncology</i> , 2017, 124, 232-239.	0.3	69
87	Reinterpretation of cross-sectional images in patients with head and neck cancer in the setting of a multidisciplinary cancer center. <i>American Journal of Neuroradiology</i> , 2002, 23, 1622-6.	1.2	69
88	Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. <i>The Journal of Supportive Oncology</i> , 2007, 5, 23-31.	2.3	67
89	Radiation-induced xerostomia. <i>Head and Neck</i> , 2007, 29, 58-63.	0.9	65
90	Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. <i>Modern Pathology</i> , 2005, 18, 315-319.	2.9	64

#	ARTICLE	IF	CITATIONS
91	Sinonasal Teratocarcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 2008, 134, 592.	1.5	64
92	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 721-729.	0.4	64
93	Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 72-77.	0.4	63
94	A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 445-452.	0.4	63
95	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. <i>Seminars in Radiation Oncology</i> , 2004, 14, 103-109.	1.0	62
96	Radiation therapy for early-stage carcinoma of the oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 743-751.	0.4	62
97	Outcomes of malignant tumors of the lacrimal apparatus. <i>Cancer</i> , 2011, 117, 2801-2810.	2.0	62
98	Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e367-e374.	0.4	62
99	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. <i>Medical Dosimetry</i> , 2016, 41, 189-194.	0.4	62
100	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021, 27, 4557-4565.	3.2	61
101	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€“Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€“based Comparison of Rigid and Deformable Algorithms. <i>Radiology</i> , 2015, 274, 752-763.	3.6	58
102	Validation of NRG oncology/RTOGâ€“0129 risk groups for HPVâ€“positive and HPVâ€“negative oropharyngeal squamous cell cancer: Implications for riskâ€“based therapeutic intensity trials. <i>Cancer</i> , 2019, 125, 2027-2038.	2.0	58
103	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. <i>Cancer</i> , 2008, 112, 111-118.	2.0	56
104	Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: A preliminary dosimetric comparison. <i>Oral Oncology</i> , 2014, 50, 746-752.	0.8	56
105	The symptom burden of treatmentâ€“naive patients with head and neck cancer. <i>Cancer</i> , 2015, 121, 766-773.	2.0	56
106	A review of neoadjuvant chemotherapy for head and neck cancer: Partially shrunken tumors may be both leaner and meaner. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 315-320.	0.4	55
107	Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: Oncologic outcome and functional assessment. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2001, 22, 329-335.	0.6	55
108	Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1692-1699.	1.3	55



#	ARTICLE	IF	CITATIONS
109	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 1653-1661.	2.0	55
110	Allograft Dermal Implant (AlloDerm) in a Previously Irradiated Field. <i>Laryngoscope</i> , 2000, 110, 934-937.	1.1	54
111	Survival Impact of Planned Restaging and Early Surgical Salvage Following Definitive Chemoradiation for Locally Advanced Squamous Cell Carcinomas of the Oropharynx and Hypopharynx. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 385-392.	0.6	54
112	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.3	54
113	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 532-540.	0.4	54
114	Acupuncture for radiation-induced xerostomia in patients with cancer: A pilot study. <i>Head and Neck</i> , 2009, 31, 1360-1368.	0.9	52
115	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	1.6	51
116	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. <i>Scientific Data</i> , 2018, 5, 180173.	2.4	51
117	Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. <i>Human Pathology</i> , 2009, 40, 283-292.	1.1	49
118	Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. <i>Head &amp; Neck Oncology</i> , 2011, 3, 32.	2.3	49
119	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. <i>Cancer</i> , 2013, 119, 3162-3169.	2.0	49
120	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 344-352.	0.4	49
121	Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916910.	2.8	49
122	High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study. <i>Head and Neck</i> , 2013, 35, 1490-1498.	0.9	48
123	Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2012, 34, 1263-1268.	0.9	48
124	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 724-733.	0.4	47
125	Molecular and Clinicopathologic Comparisons of Head and Neck Squamous Carcinoma Variants. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1299-1310.	2.1	46
126	Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 700-708.	0.4	46



#	ARTICLE	IF	CITATIONS
127	Parotidectomy in the Treatment of Aggressive Cutaneous Malignancies. <i>JAMA Otolaryngology</i> , 2002, 128, 521.	1.5	45
128	Merkel cell carcinoma of the tongue and head and neck oral mucosal sites. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2006, 101, 761-768.	1.6	45
129	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 444-449.	0.4	45
130	Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 4078-4090.	0.8	45
131	Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 2825-2843.	0.8	45
132	A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. <i>Seminars in Oncology</i> , 2004, 31, 25-28.	0.8	44
133	Meaning and the Nature of Physicians'™ Work. <i>New England Journal of Medicine</i> , 2016, 375, 1813-1815.	13.9	44
134	Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 128.	1.2	42
135	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
136	An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2013, 49, 1067-1071.	0.8	41
137	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	1.1	41
138	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 19-23.	0.9	41
139	The effect of independent collimator misalignment on the dosimetry of abutted half-beam blocked fields for the treatment of head and neck cancer. <i>Radiotherapy and Oncology</i> , 1998, 49, 273-278.	0.3	40
140	Osteoinduction Using Bone Morphogenic Protein in Irradiated Tissue. <i>JAMA Otolaryngology</i> , 1998, 124, 985.	1.5	40
141	A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. <i>Investigational New Drugs</i> , 2002, 20, 343-349.	1.2	40
142	Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. <i>Journal of Clinical Oncology</i> , 2009, 27, 4727-4732.	0.8	40
143	Effects of external beam radiation on the allograft dermal implant. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 122, 189-194.	1.1	39
144	Compliance with quality assurance measures in patients treated for early oral tongue cancer. <i>Cancer</i> , 2010, 116, 3408-3416.	2.0	39

#	ARTICLE	IF	CITATIONS
145	Prediction of Treatment Response of Head and Neck Cancers with P-31 MR Spectroscopy from Pretreatment Relative Phosphomonoester Levels. <i>Academic Radiology</i> , 2002, 9, 688-694.	1.3	38
146	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. <i>Quality of Life Research</i> , 2013, 22, 2331-2339.	1.5	38
147	Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1194-1201.	0.9	38
148	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 842-848.	1.1	37
149	Effect of Initial Treatment on Disease Outcome for Patients With Submandibular Gland Carcinoma. <i>JAMA Otolaryngology</i> , 2007, 133, 546.	1.5	36
150	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. <i>Head and Neck</i> , 2016, 38, E1472-80.	0.9	36
151	Group Therapy of Alcoholics with Concurrent Group Meetings of their Wives. <i>Quarterly Journal of Studies on Alcohol</i> , 1956, 17, 655-670.	0.3	36
152	Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. <i>Seminars in Radiation Oncology</i> , 2004, 14, 153-166.	1.0	35
153	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 687-699.	0.4	35
154	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2001, 19, 1363-1373.	0.8	34
155	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. <i>Radiation Oncology</i> , 2016, 11, 95.	1.2	34
156	Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. <i>Head and Neck</i> , 2020, 42, 1179-1186.	0.9	34
157	OUP accepted manuscript. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	0.9	34
158	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. <i>Current Oncology Reports</i> , 2005, 7, 131-136.	1.8	33
159	The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 191-198.	0.6	33
160	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. <i>Head and Neck</i> , 2016, 38, 1739-1751.	0.9	33
161	Desmoplastic neurotropic melanoma of the head and neck: The role of radiation therapy. <i>Head and Neck</i> , 2002, 24, 1068-1071.	0.9	32
162	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. <i>Head and Neck</i> , 2016, 38, E452-8.	0.9	32

#	ARTICLE	IF	CITATIONS
163	Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 180-189.	0.8	32
164	Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. <i>Head and Neck</i> , 2017, 39, 1516-1523.	0.9	32
165	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. <i>Radiotherapy and Oncology</i> , 2017, 124, 248-255.	0.3	32
166	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. <i>Practical Radiation Oncology</i> , 2015, 5, e299-e308.	1.1	31
167	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. <i>3D Printing in Medicine</i> , 2017, 3, 12.	1.7	31
168	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. <i>Npj Precision Oncology</i> , 2019, 3, 22.	2.3	31
169	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 912.	1.1	31
170	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A population-based study. <i>Head and Neck</i> , 2009, 31, 1031-1038.	0.9	30
171	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 667-677.	0.4	30
172	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. <i>Radiation Oncology</i> , 2019, 14, 148.	1.2	30
173	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. <i>Oral Oncology</i> , 2016, 61, 62-69.	0.8	29
174	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. <i>Head and Neck</i> , 2020, 42, 1939-1953.	0.9	29
175	Risk factors for clinician-reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129. <i>Cancer</i> , 2014, 120, 848-854.	2.0	28
176	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, e31-e37.	1.1	28
177	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	0.9	28
178	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1346-1354.	0.4	28
179	Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. <i>Radiotherapy and Oncology</i> , 2018, 128, 442-451.	0.3	28
180	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	2.0	28

#	ARTICLE	IF	CITATIONS
181	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 72, 90-97.	0.8	28
182	Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2014, 120, 3082-3088.	2.0	27
183	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2018, 11, 11-18.	0.9	27
184	Preliminary Investigation of Symptom Distress in the Head and Neck Patient Population. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 158-162.	0.6	26
185	Increasing Toxicity in Nonoperative Head and Neck Cancer Treatment: Investigations and Interventions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S79-S82.	0.4	26
186	Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. <i>European Journal of Cancer</i> , 2016, 64, 1-11.	1.3	26
187	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	1.0	26
188	Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2006, 263, 313-318.	0.8	25
189	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	1.2	25
190	Six habits of highly successful health information technology: powerful strategies for design and implementation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 1109-1114.	2.2	25
191	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. <i>Laryngoscope</i> , 2020, 130, 146-153.	1.1	25
192	The prevention and treatment of radiotherapy-induced xerostomia. <i>Seminars in Radiation Oncology</i> , 2003, 13, 302-308.	1.0	24
193	Phase I Study of Preoperative Radiation Therapy With Concurrent Infusional 5-Fluorouracil and Oxaliplatin Followed by Surgery and Postoperative 5-Fluorouracil Plus Leucovorin for T3/T4 Rectal Adenocarcinoma: ECOG E1297. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 108-113.	0.4	24
194	Effect of Brain Stem and Dorsal Vagus Complex Dosimetry on Nausea and Vomiting in Head and Neck Intensity-Modulated Radiation Therapy. <i>Medical Dosimetry</i> , 2011, 36, 41-45.	0.4	24
195	Superior performance of continuous over pulsatile flow ventricular assist devices in the single ventricle circulation: A computational study. <i>Journal of Biomechanics</i> , 2017, 52, 48-54.	0.9	24
196	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 16-22.	0.9	24
197	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 120-127.	0.9	24
198	Clinical Applications of Photodynamic Therapy. <i>Annals of Medicine</i> , 1994, 26, 405-409.	1.5	23

#	ARTICLE	IF	CITATIONS
199	Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 1066.	1.2	23
200	Nasopharyngeal Carcinoma Treated With External Radiotherapy, Brachytherapy, and Concurrent/Adjuvant Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 93-95.	0.6	22
201	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. <i>Head and Neck</i> , 2016, 38, E925-33.	0.9	22
202	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 362-371.	0.4	22
203	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 667-674.	0.4	21
204	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. <i>Radiotherapy and Oncology</i> , 2015, 117, 132-138.	0.3	21
205	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.3	21
206	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7078-7088.	3.2	21
207	Single-item discrimination of quality of life altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing. <i>Cancer</i> , 2019, 125, 1654-1664.	2.0	21
208	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.3	21
209	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 258-266.	0.3	21
210	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. <i>Practical Radiation Oncology</i> , 2013, 3, 186-193.	1.1	20
211	Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 765-769.	0.8	20
212	Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. <i>Head and Neck</i> , 2018, 40, 2060-2069.	0.9	20
213	p16, HPV, and Cetuximab: What Is the Evidence?. <i>Oncologist</i> , 2017, 22, 811-822.	1.9	19
214	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.3	19
215	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	2.0	19
216	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.1	18

#	ARTICLE	IF	CITATIONS
217	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. <i>Head and Neck</i> , 2017, 39, 1609-1620.	0.9	18
218	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	0.9	18
219	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	2.0	18
220	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.4	18
221	Modeling symptom drivers of oral intake in long-term head and neck cancer survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 1405-1415.	1.0	18
222	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 95-100.	0.3	18
223	We've Got a Treatment, but What's the Disease?. <i>Oncologist</i> , 1996, 1, 1-7.	1.9	18
224	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 426-436.	0.4	18
225	Dynamic Rehabilitation of the Paralyzed Face: I. Electronic Control of Reinnervated Muscles from Intact Facial Musculature in the Rabbit. <i>Otolaryngology - Head and Neck Surgery</i> , 1987, 97, 441-445.	1.1	17
226	Reversible Renal Toxicity Resulting From High Single Doses of the New Radiosensitizer Gadolinium Texaphyrin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 593-598.	0.6	17
227	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	2.0	17
228	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. <i>International Journal of Cancer</i> , 2016, 138, 1290-1297.	2.3	17
229	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	2.9	17
230	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. <i>Head and Neck</i> , 2017, 39, 633-638.	0.9	16
231	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 40-46.	0.9	16
232	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. <i>Radiotherapy and Oncology</i> , 2019, 133, 35-42.	0.3	16
233	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. <i>International Journal of Particle Therapy</i> , 2016, 2, 533-543.	0.9	16
234	Metronidazole in Head and Neck Surgery—The Effect of Lengthened Prophylaxis. <i>Otolaryngology - Head and Neck Surgery</i> , 1990, 103, 1009-1011.	1.1	15



#	ARTICLE	IF	CITATIONS
235	A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. <i>Medical and Pediatric Oncology</i> , 2001, 37, 390-392.	1.0	15
236	Controversies in the management of advanced laryngeal squamous cell carcinoma. <i>Cancer</i> , 2004, 101, 211-219.	2.0	15
237	Outcomes of patients with tonsillar carcinoma treated with posttonsillectomy radiation therapy. <i>Head and Neck</i> , 2010, 32, 473-480.	0.9	15
238	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. <i>Head and Neck</i> , 2017, 39, 2079-2087.	0.9	15
239	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	0.9	15
240	Head and neck squamous cell carcinoma: optimizing the therapeutic index. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 501-514.	1.1	14
241	Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. <i>Head and Neck</i> , 2013, 35, 321-328.	0.9	14
242	Outcomes for hypopharyngeal carcinoma treated with organ preservation therapy. <i>Head and Neck</i> , 2016, 38, E2091-9.	0.9	14
243	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching liquid biopsy and quantitative tumor modeling. <i>BMC Cancer</i> , 2018, 18, 903.	1.1	14
244	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. <i>Radiotherapy and Oncology</i> , 2019, 130, 46-55.	0.3	14
245	Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. <i>Head and Neck</i> , 2020, 42, 3326-3335.	0.9	14
246	Pilot Study of Organ Preservation Multimodality Therapy for Locally Advanced Resectable Oropharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 509-515.	0.6	13
247	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organs-at-risk margination using daily CT on-rails imaging. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 159-169.	0.8	13
248	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	0.8	13
249	Prospective analysis of in vivo landmark point-based MRI geometric distortion in head and neck cancer patients scanned in immobilized radiation treatment position: Results of a prospective quality assurance protocol. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 13-19.	0.9	13
250	Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. <i>Head and Neck</i> , 2013, 35, 1454-1460.	0.9	12
251	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	1.0	12
252	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 185-193.	0.4	12

#	ARTICLE	IF	CITATIONS
253	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 567-572.	0.6	12
254	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. <i>Oral Oncology</i> , 2021, 113, 105125.	0.8	12
255	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 21-27.	0.3	12
256	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1708-1709.	0.8	11
257	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	0.9	11
258	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 71-78.	0.9	11
259	Outcomes after radiation therapy for <scp>T2N0</scp>/stage <scp>II</scp> glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 2791-2800.	0.9	11
260	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 148, 133-139.	0.3	11
261	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 54.	1.3	11
262	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	0.9	11
263	Final Report of a Pilot Trial of Accelerated Radiotherapy Plus Concurrent 96-Hour Infusional Paclitaxel for Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 595-602.	0.6	10
264	Development of a Software for Quantitative Evaluation Radiotherapy Target and Organ-at-Risk Segmentation Comparison. <i>Journal of Digital Imaging</i> , 2014, 27, 108-119.	1.6	10
265	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. <i>Head and Neck</i> , 2016, 38, E580-7.	0.9	10
266	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. <i>Radiotherapy and Oncology</i> , 2020, 151, 119-125.	0.3	10
267	Method comparison of automated matching software-assisted cone-beam CT and stereoscopic kilovoltage x-ray positional verification image-guided radiation therapy for head and neck cancer: a prospective analysis. <i>Physics in Medicine and Biology</i> , 2009, 54, 7401-7415.	1.6	9
268	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 1-5.	1.2	9
269	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. <i>Radiation Oncology</i> , 2017, 12, 129.	1.2	8
270	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	2.0	8

#	ARTICLE	IF	CITATIONS
271	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	0.6	8
272	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. <i>International Journal of Particle Therapy</i> , 2021, 8, 108-118.	0.9	8
273	Direct Nerve Implantation Vs. Nerve-Muscle Pedicle: A Comparative Study of Reinnervation in the Rabbit. <i>Otolaryngology - Head and Neck Surgery</i> , 1989, 100, 126-133.	1.1	7
274	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. <i>Oral Oncology</i> , 2016, 63, 16-22.	0.8	7
275	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 638-644.	0.4	7
276	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. <i>Advances in Radiation Oncology</i> , 2020, 5, 1359-1363.	0.6	7
277	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 98-103.	0.9	7
278	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-effects model analysis of a prospective observational cohort registry. <i>Cancer</i> , 2021, 127, 2453-2464.	2.0	7
279	Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. <i>BMC Cancer</i> , 2021, 21, 446.	1.1	7
280	Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 4413-4420.	2.0	7
281	An Advanced Communication Skills Workshop Using Standardized Patients for Senior Medical Students. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2021, 17, 11163.	0.5	7
282	Hypopharyngeal Desmoid Tumor. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 123, 279-281.	1.1	6
283	Modification of Gill-Thomas-Cosman frame for extracranial head-and-neck stereotactic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1192-1195.	0.4	6
284	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018, 79, 1-8.	0.8	6
285	Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. <i>Head and Neck</i> , 2019, 41, 3924-3932.	0.9	6
286	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. <i>Journal of Neurosurgery</i> , 2019, 130, 812-821.	0.9	6
287	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. <i>Oral Oncology</i> , 2020, 106, 104665.	0.8	6
288	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. <i>Scientific Data</i> , 2020, 7, 63.	2.4	6

#	ARTICLE	IF	CITATIONS
289	Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2021, 127, 1238-1245.	2.0	6
290	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores â€œ A pooled analysis of RTOG 0129 and 0522. <i>Oral Oncology</i> , 2021, 116, 105241.	0.8	6
291	<sup>18</sup> F-FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 93-101.	0.9	6
292	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	6
293	The effects of mephenesin and practice on the Bender-Gestalt performance of psychiatric outpatients. <i>Journal of Clinical Psychology</i> , 1955, 11, 90-92.	1.0	5
294	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. <i>Cancer</i> , 2006, 106, 1950-1957.	2.0	5
295	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. <i>Head and Neck</i> , 2014, 36, 819-825.	0.9	5
296	Cognitive function and patientâ€™reported memory problems after radiotherapy for cancers at the skull base: A crossâ€™sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€™Head and Neck Module. <i>Head and Neck</i> , 2017, 39, 2048-2056.	0.9	5
297	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 98-105.	0.9	5
298	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. <i>Cancer</i> , 2021, 127, 2916-2925.	2.0	5
299	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 469-476.	0.4	4
300	Instant replay. <i>Healthcare</i> , 2013, 1, 52-54.	0.6	4
301	Auto-segmentation of the brachial plexus assessed with TaCTICS â€œ A software platform for rapid multiple-metric quantitative evaluation of contours. <i>Acta OncolÃ³gica</i> , 2015, 54, 562-566.	0.8	4
302	Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2015, 10, 1667-1673.	1.7	4
303	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. <i>Radiotherapy and Oncology</i> , 2021, 157, 63-69.	0.3	4
304	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. <i>International Journal of Particle Therapy</i> , 2021, 8, 261-272.	0.9	4
305	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. <i>International Journal of Particle Therapy</i> , 2021, 8, 234-247.	0.9	4
306	Significant Variation in Exercise Recommendations for Youth With Cardiomyopathies or Fontan Circulation. <i>Circulation: Heart Failure</i> , 2021, 14, e008738.	1.6	4

#	ARTICLE	IF	CITATIONS
307	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 38-45.	0.5	4
308	Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival. <i>Oral Oncology</i> , 2022, 130, 105906.	0.8	4
309	RE: SF2: Clothes for the emperor?. <i>Radiotherapy and Oncology</i> , 1995, 34, 81.	0.3	3
310	Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 715-717.	0.4	3
311	A prospective evaluation of health-related quality of life after skull base re-irradiation. <i>Head and Neck</i> , 2020, 42, 485-497.	0.9	3
312	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. <i>Head and Neck</i> , 2020, 42, 2137-2144.	0.9	3
313	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. <i>Practical Radiation Oncology</i> , 2020, 10, 363-371.	1.1	3
314	Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 37-44.	0.8	3
315	Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021, 144, 169-177.	1.3	3
316	Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	0.9	3
317	Tips for Building a Community for Incoming Medical Students Virtually in the COVID-19 Era. <i>Medical Science Educator</i> , 2021, 31, 1-8.	0.7	3
318	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	0.9	3
319	Does concurrent postoperative radiotherapy and chemotherapy in head and neck cancer improve patient outcome?. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 14-15.	4.3	2
320	Established and Emerging Uses of Cytoprotection in Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2006, 132, 129.	1.5	2
321	Comparison of measurement methods with a mixed effects procedure accounting for replicated evaluations (COM3PARE): method comparison algorithm implementation for head and neck IGRT positional verification. <i>BMC Medical Imaging</i> , 2015, 15, 35.	1.4	2
322	In Regard to Bossi et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 669-670.	0.4	2
323	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 29-34.	1.2	2
324	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	2.0	2

#	ARTICLE	IF	CITATIONS
325	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. <i>Head and Neck</i> , 2021, 43, 1592-1603.	0.9	2
326	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 213-222.	0.9	2
327	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. <i>Balkan Medical Journal</i> , 2016, 33, 339-343.	0.3	2
328	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2
329	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 3411-3412.	2.0	1
330	Factors associated with complex oral treatment device usage in patients with head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 78-83.	0.9	1
331	Therapeutic approaches and outcomes in patients with larynx or hypopharynx highâ€grade neuroendocrine carcinoma: A singleâ€center retrospective analysis. <i>Head and Neck</i> , 2021, 43, 3788-3795.	0.9	1
332	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. <i>Acta OncolÃ³gica</i> , 2022, 61, 146-152.	0.8	1
333	Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. <i>Advances in Radiation Oncology</i> , 2022, 7, 100989.	0.6	1
334	Head and Neck Radiation Therapy: Basic and Advanced Techniques. <i>Otolaryngology - Head and Neck Surgery</i> , 1995, 112, P115-P115.	1.1	0
335	Dosimetric comparison of centered and off-centered posterior neck electron fields. <i>Medical Dosimetry</i> , 1998, 23, 284-287.	0.4	0
336	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. <i>Medical Dosimetry</i> , 2004, 29, 86-91.	0.4	0
337	Postoperative treatment intensification for improving outcome in the high-risk patient: An evolutionary process. <i>Head and Neck</i> , 2005, 27, 841-842.	0.9	0
338	Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 38-45.	0.5	0
339	Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2755-2760.	0.7	0
340	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2011, , 613-628.		0
341	Multidisciplinary Management of Oropharynx Carcinomas. , 2011, , 401-430.		0
342	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2016, , 753-767.		0



#	ARTICLE	IF	CITATIONS
343	Multidisciplinary Management of Oropharynx Carcinomas. , 2016, , 475-510.		0
344	Employee Physical Activity in an Outpatient Oncology Clinic: A Baseline Pilot Study. Cureus, 2018, 10, e3803.	0.2	0
345	Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2006, 1, 38-45.	0.5	0
346	Cross-Cultural Brain Activity Differences Between True and Sham Acupuncture for Xerostomia During Head and Neck Cancer Radiotherapy. Integrative Cancer Therapies, 2022, 21, 153473542211016.	0.8	0